Artificial intelligence is advancing rapidly in drug discovery as pharmaceutical and biotech companies look for ways to shave years off R&D timelines and increase the chances…
Palace intrigue may dominate the news cycle surrounding OpenAI, but the AI startup — and its accelerator programs — is moving along, its PR team tells…
